Avacta selects chemotherapy drug candidate for pre-clinical development
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
List view / Grid view
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Urea cycle disorders affect the liver’s ability to excrete urea from the body. To test potential therapeutics requires an accurate model – a hurdle that has now been successfully navigated thanks to a team of researchers in Switzerland.
Sino Biological has announced that its new location in Houston, Texas, is now open, expanding the company geographically.
In this latest episode, we discuss how small molecule discovery can be automated and how this process saves researchers time and money.
Altasciences has announced its acquisition of Sinclair Research, a pre-clinical CRO, to expand its services across the US.
A team of researchers in the US has devised a new means of removing excess chemotherapy drugs from a patient’s bloodstream, with potential for wider clinical and materials science applications.
In this Q&A, Professor Ross King from the University of Cambridge, UK, discusses how a new machine learning approach could aid drug discovery and development. The method learns from multiple problems and improves performance while it learns.
Learn about how Thermo Scientific™ Watson LIMS™ software can help manage bioanalytical studies, working to industry and regulatory standards for small and large molecule testing.
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
With operations in over 100 countries worldwide, GenScript Biotech, an industry leader in biotechnology reagent services, has established a new UK office in the Oxford area to better connect with the UK biosciences sector.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
In this podcast, join Tyler Pascoe and Matt Gruver from Thermo Fisher Scientific as they explore the new Watson LIMS software.